We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ResMed Inc. (RMD - Free Report) announced third-quarter fiscal 2017 adjusted earnings per share (EPS) of 71 cents, up 2.8% from the prior-year quarter level. Earnings also beat the Zacks Consensus Estimate by a penny.
Including one-time items, ResMed reported EPS of 62 cents in the quarter, down 3.1% year over year.
Revenues in Details
Revenues in the reported quarter increased 13.3% year over year (up 14% at constant exchange rate or CER) to $514.2 million. The figure however missed the Zacks Consensus Estimate of $519.6 million.
On a geographic basis, revenues in the Americas rose 18% year over year to $332.1 million, which included Brightree revenues of $35.0 million. Excluding Brightree, revenues in the Americas totaled $297.1 million, reflecting a 5% increase over the prior year quarter. Revenues in combined EMEA and APAC were $182.1 million, highlighting a 9% rise at CER, compared to the same period last year.
Adjusted gross margin expanded 103 basis points (bps) year over year to 58.3% in the reported quarter. Selling, general and administrative expenses were up 15.5% year over year to $137.8 million, while there was a 24.9% increase in Research and Development expenses to $35.1 million. This led to a 17.3% rise in adjusted operating expenses, which amounted to $172.9 million. Accordingly, adjusted operating margin in the quarter contracted 13 bps to 24.6%.
Financial Update
ResMed exited third-quarter 2017 with cash and cash equivalents of $827.3 million, compared with $788.1 million in the second quarter.
Year to date, the company generated $273.7 million of cash flow from operations, down from the year-ago figure of $404.9 million, displaying weak underlying earnings and a decline in net working capital balances.
Concurrent to its third-quarter earnings release, ResMed announced a quarterly dividend of 33 cents per share, representing a 10% increase from the company’s prior payout. The dividend will be paid on Jun 15, to shareholders of record as on May 11.
As previously declared, ResMed temporarily suspended its share repurchase program due to recent acquisitions. However, the company still expects to recommence the buy-back program sometime in fiscal 2018.
Guidance
Management expects SG&A expenses, as a percentage of revenues, in the band of 26%–27%. R&D expenses, as a percentage of revenues, are projected at 7% for fourth-quarter 2017. This reflects marketing expenses associated with product launches along with the ongoing legal expenses.
Our Take
ResMed exited the third quarter on a mixed note with earnings beating the Zacks Consensus Estimate and sales missing the mark. Challenges like competitive bidding and reimbursement issues continue to plague the stock. Foreign exchange movements dented third-quarter earnings by a penny, thanks to the weaker Euro and stronger Australian dollar relative to the U.S. dollar.
On the bright side, the company achieved solid double-digit global revenue growth this quarter, led by sales from Software-as-a-Service businesses as well as its new mask products. The company also launched the ResMed AirMini during the reported quarter. All these factors boost investor faith in the stock.
Zacks Rank & Key Picks
ResMed currently has a Zacks Rank #4 (Sell). Better-ranked stocks in the broader Medical space include Inogen, Inc. (INGN - Free Report) , ZELTIQ Aesthetics, Inc. and Hill-Rom Holdings, Inc. . While Inogen and ZELTIQ Aesthetics sport a Zacks Rank #1 (Strong Buy), Hill-Rom carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen gained 53.4% in the last one year, compared with the S&P 500’s gain of 15.6%. The company reported a stellar four-quarter positive average earnings surprise of over 49.08%.
ZELTIQ Aesthetics surged 88.9% in the last one year, in comparison to the S&P 500. Its four-quarter average earnings surprise was a positive 12.03%.
Hill-Rom gained over 52.7% in the past one year, better than the S&P 500 mark. It posted a trailing four-quarter positive average earnings surprise of 3.1%.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trade>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
ResMed (RMD) Beats Q3 Earnings, Misses Sales Estimates
ResMed Inc. (RMD - Free Report) announced third-quarter fiscal 2017 adjusted earnings per share (EPS) of 71 cents, up 2.8% from the prior-year quarter level. Earnings also beat the Zacks Consensus Estimate by a penny.
Including one-time items, ResMed reported EPS of 62 cents in the quarter, down 3.1% year over year.
Revenues in Details
Revenues in the reported quarter increased 13.3% year over year (up 14% at constant exchange rate or CER) to $514.2 million. The figure however missed the Zacks Consensus Estimate of $519.6 million.
ResMed Inc. Price, Consensus and EPS Surprise
ResMed Inc. Price, Consensus and EPS Surprise | ResMed Inc. Quote
On a geographic basis, revenues in the Americas rose 18% year over year to $332.1 million, which included Brightree revenues of $35.0 million. Excluding Brightree, revenues in the Americas totaled $297.1 million, reflecting a 5% increase over the prior year quarter. Revenues in combined EMEA and APAC were $182.1 million, highlighting a 9% rise at CER, compared to the same period last year.
Adjusted gross margin expanded 103 basis points (bps) year over year to 58.3% in the reported quarter. Selling, general and administrative expenses were up 15.5% year over year to $137.8 million, while there was a 24.9% increase in Research and Development expenses to $35.1 million. This led to a 17.3% rise in adjusted operating expenses, which amounted to $172.9 million. Accordingly, adjusted operating margin in the quarter contracted 13 bps to 24.6%.
Financial Update
ResMed exited third-quarter 2017 with cash and cash equivalents of $827.3 million, compared with $788.1 million in the second quarter.
Year to date, the company generated $273.7 million of cash flow from operations, down from the year-ago figure of $404.9 million, displaying weak underlying earnings and a decline in net working capital balances.
Concurrent to its third-quarter earnings release, ResMed announced a quarterly dividend of 33 cents per share, representing a 10% increase from the company’s prior payout. The dividend will be paid on Jun 15, to shareholders of record as on May 11.
As previously declared, ResMed temporarily suspended its share repurchase program due to recent acquisitions. However, the company still expects to recommence the buy-back program sometime in fiscal 2018.
Guidance
Management expects SG&A expenses, as a percentage of revenues, in the band of 26%–27%. R&D expenses, as a percentage of revenues, are projected at 7% for fourth-quarter 2017. This reflects marketing expenses associated with product launches along with the ongoing legal expenses.
Our Take
ResMed exited the third quarter on a mixed note with earnings beating the Zacks Consensus Estimate and sales missing the mark. Challenges like competitive bidding and reimbursement issues continue to plague the stock. Foreign exchange movements dented third-quarter earnings by a penny, thanks to the weaker Euro and stronger Australian dollar relative to the U.S. dollar.
On the bright side, the company achieved solid double-digit global revenue growth this quarter, led by sales from Software-as-a-Service businesses as well as its new mask products. The company also launched the ResMed AirMini during the reported quarter. All these factors boost investor faith in the stock.
Zacks Rank & Key Picks
ResMed currently has a Zacks Rank #4 (Sell). Better-ranked stocks in the broader Medical space include Inogen, Inc. (INGN - Free Report) , ZELTIQ Aesthetics, Inc. and Hill-Rom Holdings, Inc. . While Inogen and ZELTIQ Aesthetics sport a Zacks Rank #1 (Strong Buy), Hill-Rom carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Inogen gained 53.4% in the last one year, compared with the S&P 500’s gain of 15.6%. The company reported a stellar four-quarter positive average earnings surprise of over 49.08%.
ZELTIQ Aesthetics surged 88.9% in the last one year, in comparison to the S&P 500. Its four-quarter average earnings surprise was a positive 12.03%.
Hill-Rom gained over 52.7% in the past one year, better than the S&P 500 mark. It posted a trailing four-quarter positive average earnings surprise of 3.1%.
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors. Click here for Zacks' secret trade>>